Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.

Natalie DanzigerEthan S SokolRyon P GrafMatthew C HiemenzJake MauleVamsi ParimiCarlo PalmieriLajos PusztaiJeffrey S RossRichard S P Huang

Published in: The oncologist (2023)

The subtypes of breast cancer have distinct patterns of PD-L1 expression, supporting that further research of immunotherapies may include specific evaluation of optimum cutoffs for non-TNBC patients. In TNBC, PD-L1 positivity is not associated with other clinicopathologic or genomic features and should be integrated into future studies of immunotherapy efficacy.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
prognostic factors
high throughput
current status
copy number